The Anglo-Scandinavian cardiac outcomes trial (ASCOT)—demography of first 15000 patients randomised

The Anglo-Scandinavian Cardiac Outcomes Trial: implications and further outcomes.

A t a meeting of the European Blood Pressure Group held in Madonna di Campiglio, Italy, in the spring of 1988, concern was expressed that there were no plans to evaluate the long-term efficacy of newer classes of blood pressure– lowering drugs, including the calcium channel blockers and the angiotensin-converting enzyme inhibitors, in morbidity and mortality outcome trials. These drugs were bei...

Anglo-Scandinavian cardiac outcomes trial--lipid lowering arm.

OBJECTIVE Older patients experience higher rates of cardiovascular disease than younger patients, but may be undertreated with statins due to doubts about efficacy and safety. The Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial allowed an evaluation of the efficacy and safety of atorvastatin among older (≥ 65 years) and younger (<65 years) patients with hypertension. METHO...

Brief Reviews The Anglo-Scandinavian Cardiac Outcomes Trial Implications and Further Outcomes

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.

AIMS To determine the cardiovascular benefits in those originally assigned atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-2.2 years after closure of the lipid-lowering arm of the trial (ASCOT-LLA). METHODS AND RESULTS The Blood Pressure Lowering Arm of the ASCOT trial (ASCOT-BPLA) compared two different antihypertensive treatment strategies on cardiovascular outcomes. ASCOT-LLA...

Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudy.

Changes in the retinal microcirculation are associated with hypertension and predict cardiovascular mortality. There are few data describing the impact of antihypertensive therapy on retinal vascular changes. This substudy of the Anglo-Scandinavian Cardiac Outcomes Trial compared the effects of an amlodipine-based regimen (373 patients) with an atenolol-based regimen (347 patients) on retinal m...